（Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial）⭐5. WU-CART-007（Wugen 的CD7-CAR-T，Ⅱ期）—公开的IND效果好，预计主要副作用是T细胞再生障碍 目前只有IND数据。（1）策略：为了产生WU-CART-007细胞，使用CRISPR / Cas9...
CAS号: 英文名: CD7 (T Cells and NK Cells) 英文别名: CD7 (T Cells and NK Cells) 中文名: 中文别名: CBNumber: CB71007614 分子式: 分子量: 0 MOL File: Mol file 化学性质 安全信息 用途 供应商 1 CD7 (T Cells and NK Cells)化学性质 ...
Reinhold U, Liu L, Sesterhenn J, Schnautz S and Abken H (1996) The CD77 T cell subset represents the majority of IL-5-secreting cells within CD4+CD45RA7 T cells. Clin. Exp. Immunol. 106: 555 ± 559Reinhold,U., Liu,L., Sesterhenn,J., Schnautz,S. and Abken,H. The CD7- ...
他们新的简化方法选择了一种有利的T细胞类型,并在实验室中显示出对抗复发的T细胞急性淋巴细胞白血病(T-ALL)的前景。相关研究结果于2022年8月1日在线发表在Blood期刊上,论文标题为“Engineering Naturally Occurring CD7 Negative T Cells for the Immunotherapy of Hematological Malignancies”。 急性淋巴细胞白血病(ALL)...
(Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial) 5. WU-CART-007(Wugen 的CD7-CAR-T,Ⅱ期)—公开的IND效果好,预计主要副作用是T细胞再生障碍 目前只有IND数据。
⭐4.CAR-T(北京博仁医院CD7-CAR-T,Ⅱ期)—Ⅰ期数据显示完全缓解的有效性,可控的安全性 (Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial) ⭐5. WU-CART-007(Wugen 的CD7-CAR-T,Ⅱ期)—公开的I...
T cells regenerating after lymphodepletion lacked CD7 expression, were polyclonal and responded to SARS-CoV-2 vaccination; CD7+ immune cells reemerged concomitantly with CAR T cell disappearance. In conclusion, autologous anti-CD7 PEBL-CAR T cells have powerful antileukemic activity and are potentially...
(Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial) ⭐5. WU-CART-007(Wugen 的CD7-CAR-T,Ⅱ期)—公开的IND效果好,预计主要副作用是T细胞再生障碍 目前只有IND数据。
3. Abstract #369678 Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia. 潘静 教授 副主任医师;医学硕士,免疫学博士 中国抗癌协会小儿肿瘤专业委员会 专业委员 中国抗癌协会血液肿瘤专业委员会 青年委员 ...
参考文献:Eradication of T-ALL cells by CD7 targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management,doi:10.1158/1078-0432.CCR-20-1271; 识别微信二维码,添加生物制品圈小编,符合条件者即可加入生物制品微信群! 请注明:姓名+研究方向!